NAKA trades 100.5% below Wall Street's consensus target of $8.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NAKA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Nakamoto Inc. (NAKA) has a Wall Street consensus price target of $8.00, based on estimates from 2 covering analysts. With the stock currently trading at $3.99, this represents a potential upside of +100.5%. The company has a market capitalization of $69M.
Analyst price targets range from a low of $8.00 to a high of $8.00, representing a 0% spread in expectations. The median target of $8.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NAKA trades at a trailing P/E of -0.4x. Analysts expect EPS to grow +56.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
OPRXOptimizeRx Corporation | $118M | $6.29 | $10.50 | +66.9% | Buy | 6.7x | 15 |
TALKTalkspace, Inc. | $871M | $5.20 | $5.25 | +1.0% | Hold | 40.2x | 10 |
DOCSDoximity, Inc. | $4.3B | $22.74 | $29.47 | +29.6% | Hold | 15.9x | 23 |
HIMSHims & Hers Health, Inc. | $7.9B | $36.17 | $28.69 | -20.7% | Hold | — | 20 |
WELLWelltower Inc. | $166.5B | $237.59 | $237.80 | +0.1% | Buy | 82.0x | 35 |
TDOCTeladoc Health, Inc. | $1.6B | $9.10 | $7.40 | -18.7% | Hold | — | 42 |
AMWLAmerican Well Corporation | $150M | $8.99 | $6.33 | -29.6% | Hold | — | 15 |
GDRXGoodRx Holdings, Inc. | $1.1B | $3.03 | $3.08 | +1.7% | Hold | 9.8x | 24 |
CVSCVS Health Corporation | $133.1B | $104.33 | $103.64 | -0.7% | Buy | 14.1x | 41 |
UNHUnitedHealth Group Incorporated | $388.9B | $428.19 | $426.75 | -0.3% | Buy | 23.3x | 52 |
Quick answers to the most common questions about buying NAKA stock.
The consensus Wall Street price target for NAKA is $8, representing 100.5% upside from the current price of $3.99. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NAKA has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $8 implies 100.5% upside from current levels.
NAKA's current price is $3.99 with a consensus target of $8 (100.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $8 for NAKA, while the most conservative target is $8. The consensus of $8 represents the median expectation. These targets typically reflect 12-month expectations.
NAKA is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NAKA stock forecast based on 2 Wall Street analysts shows a consensus price target of $8, with estimates ranging from $8 (bear case) to $8 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on NAKA, with a "Buy" consensus rating and $8 price target (100.5% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NAKA analyst price targets range from $8 to $8, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.